SUMMARY Background
Ledipasvir and sofosbuvir is a well-tolerated regimen with high sustained virological response (SVR) rates in pre-liver transplant patients infected with chronic hepatitis C virus (HCV), but data in liver transplant recipients outside of clinical trials is limited.
Aim
To address this knowledge gap and assess SVR rates without the use of ribavirin in liver transplant recipients Methods This is a retrospective study examining the treatment of 75 post-liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Differences between SVR cohorts and predictors of SVR were analysed in an intentionto-treat (ITT) fashion.
Results
A total of 408 genotype 1, HCV patients were treated with ledipasvir/sofosbuvir from October 2014 to August 2015 at our centre. Seventy-three patients were post-liver transplant and were treated with a median of 2.9 years from transplant. Ledipasvir/sofosbuvir achieved an SVR12 of 95.9%. African Americans made up 28.8% of the cohort. Sixty-three per cent of patients were treated previously, including 13.7% of patients previously treated with direct-acting antivirals. Only 2.7% had recurrent allograft cirrhosis, and the majority (90.4%) was on calcineurin inhibitor based immunosuppressive therapy. Approximately 82% of patients had chronic kidney disease (CKD) stage 2 or 3. In univariate logistic regression, only detectable week 8 viral load was predictive of failure to achieve SVR.
Conclusion
Our data confirm excellent SVR outcomes and favourable safety and tolerability profiles with ledipasvir/sofosbuvir without ribavirin in post-liver transplant recipients infected with HCV, despite treatment guidelines to use ribavirin. HCV-related liver disease is the most common indication for liver transplantation (LT) in the USA today, and recurrent HCV infection in the liver allograft is universal in the absence of effective anti-viral therapy. [1] [2] [3] Recurrent HCV after LT is historically associated with reduced graft and patient survival and has been the most common cause of graft and patient loss. 1, 3 Interferon-based
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anti-viral regimens have poor efficacy, tolerability and an increased risk of adverse reactions including risk of allograft rejection in post-liver transplant recipients. [4] [5] [6] The recent development of all oral direct-acting antiviral (DAA) agents has changed the landscape of HCV anti-viral therapy, obviating the need for concurrent interferon and leading to high SVR rates with minimal side effects. Ledipasvir/Sofosbuvir is a potent NS5A plus NS5B polymerase inhibitor combination active against HCV genotypes 1, 4 and 6.
7 Clinical trials for ledipasvir/sofosbuvir resulted in SVR rates upwards of 90%. [8] [9] [10] [11] Treating transplant recipients prior to HCV recurrence in the allograft is not only a desirable outcomes but also cost-effective. 12 In previous regimens, effectiveness studies often proved disappointing compared to clinical trials, largely due to unanticipated adverse events in a sicker, "real world" population. Ledipasvir/sofosbuvir appears to have effectiveness more closely approximating efficacy. In a recent study of over 4000 genotype 1 treatment-na€ ıve patients by Backus et al., SVR rates with ledipasvir/sofosbuvirAEribavirin nearly matched the rates in clinical trials. 13 
METHODS
Subjects for this retrospective cohort study were selected from the Emory Transplant Center (Figure 1 ), a high volume transplant hepatology specialty clinic in Atlanta, GA. The study protocol was approved by the Emory Institutional Review Board. Inclusion criteria were postliver transplant status and recurrent genotype 1 HCV infection in the allograft treated with ledipasvir/ sofosbuvir for at least 1 week during the study time period of October 2014 to August 2015. The final treatment duration was at the discretion of the providing transplant hepatologist. Chart reviews of the Emory electronic medical record (Cerner Powerchart, Atlanta, GA, USA) were performed by the authors using clinical notes, pathology records, and laboratory values to identify demographic and clinical characteristics and laboratory results. The primary variable examined was SVR12, defined as undetectable viral load (VL) 12 weeks after end of therapy. Failure to achieve SVR12 could occur in four ways: (i) Relapse: undetectable VL at end of therapy but positive within the 12 weeks after therapy completion; (ii) Non-response: unable to reach undetectable viral load while on therapy; (iii) Viral break-through: undetectable viral load followed by detectable viral load while on treatment or (iv) Early cessation secondary to intolerance or death.
Independent variables included clinical and laboratory patient characteristics at the beginning of therapy and with serial HCV viral load monitoring. Missed viral load draws at end of treatment or post-treatment were considered negative if subsequent lab draws confirmed an undetectable viral load. Missed viral load draws at any time period were inferred from recent or subsequent results if possible (i.e. they were considered negative if the previous and subsequent result was also negative); otherwise, they were left missing. Given variability in reporting of viral load from extra-institutional laboratories, the viral load was considered undetectable if reported as "negative" or "<15 IU/mL." Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease (MDRD) 6 equation. An ITT approach was used. Early terminators were considered failures. Fibrosis stage was determined by biopsy if available; otherwise, patients were considered noncirrhotic unless they had documented radiographic or clinical evidence of cirrhosis. If fibrosis was reported between stages, the higher stage was used.
Statistical analysis
Baseline characteristics and SVR comparisons by subpopulations were conducted using the Chi-squared test, Fisher's Exact test, Student's t-test or the Wilcoxon Rank Sum test as appropriate. Logistic regression was conducted on all potential predictors of SVR failure. Variables that were significant in univariate modelling (P ≤ 0.10) were eligible for entry into a multivariable model. Significance in the multivariable model was defined as a P < 0.05. SAS 9.4 was used for statistical analysis (SAS Institute, Cary, NC, USA).
RESULTS
Between October 2014 and August 2015, a total of 408 genotype 1 patients began treatment with ledipasvir/sofosbuvir at our institution; of these, 334 patients were nontransplant recipients and one patient stopped therapy after less than 1 week after deciding to pursue hospice ( Figure 1 ). Of the remaining 73 liver transplant patients, there were three treatment failures including one nonresponse, one break-through and one relapse. The patient with nonresponse was terminated after 16 weeks of a planned 24 weeks. The break-through was terminated at week 17 of planned 24. The relapse completed a 12 week course of therapy. All patients reached desired treatment endpoints, that is, either completed planned therapy or treatment was terminated due to failure. No patients in the study cohort were terminated early because of illness, death or intolerability. The mean age (standard deviation, s.d.) was 60.8 (6.7). The cohort was 75.3% male, 68.5% Caucasian, and 28.8% African-American. Patients with previous treatment experience made up 63.0% of the cohort, including 13.7% of patients who were previously treated with DAAs. Roughly 85% (n = 62) of patients had biopsy data for staging with a median (interquartile range, IQR) time between biopsy and treatment initiation of 266.5 days (148-464). A minority of the patients had recurrent allograft cirrhosis (2.7%). The majority was on CNI based immunosuppressive therapy (90.4%). Approximately, 82% of patients had CKD stage 2 or 3. Mean GFR was 66.8 at initiation and never fell below 64 at measured time periods. The median (IQR) time from liver transplant to anti-viral therapy was 2.9 (1.1-5.4) years. The majority of patients (76. (Table 1a and b). Approximately 74% of the patients achieved an undetectable viral load by week 4, and 97.1% were undetectable at week 8 of therapy. No difference was seen between the SVR cohorts according to age, race, BMI, genotype, viral load or creatinine (Table 2 ). Figure 2 depicts comparisons of SVR rates in various subpopulations. There were no statistically significant differences in SVR rates according to gender, race, prior treatment or CKD. There was a trend towards significance according to viral load status at week 8 of treatment (P = 0.082). The univariate analysis for predictors of SVR failure is shown in Table 3 . Only a positive viral load at week 8 of treatment (OR: 33.00, 95% CI: 1.47-738.68, P = 0.028) reached the a priori definition of statistical significance; therefore, no multivariable models were performed. A subgroup analysis including only those patients who received 12 or 16 weeks of therapy (n = 60) was conducted to explore the potential of using a positive week 8 VL as an indication to prolong therapy. The analysis failed because no patients in the subcohort had a positive week 8 viral load.
DISCUSSION
Our analysis suggests excellent SVR rates with ledipasvir/ sofosbuvir in a post-transplant cohort despite the lack of ribavirin, which argues against current guideline-based recommendations. The benefit of adding ribavirin to DAA regimens remains unclear. In a large cohort of Veterans with genotype 1 HCV, the use of ribavirin did not significantly alter SVR rates in several DAA regimens. 15 Nevertheless, current AASLD and IDSA guidelines for treatment-na€ ıve and -experienced liver transplant recipients with HCV genotype 1 infection recommend ledipasvir/sofosbuvir with weight-based ribavirin. These guidelines relied mostly upon results from the SOLAR-1 study which was a large multicentre, randomised controlled trial that included 223 post-liver transplant recipients. On an intention-to-treat basis, SVR was achieved in 96% of patients with Metavir fibrosis stages F0 to F3 and in 96% of patients with compensated cirrhosis. All patients received a combination of ledipasvir/ sofosbuvir with ribavirin. These results were again replicated in the SOLAR-2 study, which was conducted in Europe, Australia, and New Zealand. Because the benefit of ribavirin could not be ascertained from the SOLAR studies, and published data examining the efficacy and effectiveness of a ribavirin-free regimen are lacking for post-liver transplant patients, current guidelines presume that ribavirin may contribute to the high SVR12 rates observed in these clinical trials. The decision to use ribavirin, especially in this population, is not trivial because it has several significant adverse effects which affect quality of life and lead to poor outcomes. It is directly toxic to red blood cells, resulting in a median decline in haemoglobin of approximately 3 g/dL. 16, 17 Post-LT patients are already susceptible to anaemia secondary to their use of bone marrow suppressing medications. Additional side effects include rash, gastrointestinal symptoms such as nausea, anorexia, and diarrhoea and limited use in patients with severe renal impairment. In fact, in a recent health-related quality of life study, patients receiving interferon and/or ribavirin containing regiments in addition to DAAs reported a significantly lower quality of life than those patients who were treated without interferon and/or ribavirin. 18 In addition, the exact antiviral mechanism translating into shorter treatment duration and improved SVR rates with ribavirin in advanced cirrhotics undergoing treatment with ledipasvir/sofosbuvir is unclear. Few patients in our cohort had advanced liver disease or portal hypertension. Indeed, few post-transplant patients undergoing HCV therapy in the new era of direct-acting antivirals will have advanced liver disease, underscoring the potential futility in adding ribavirin. There is only one large multicentre study and a few smaller studies published in abstract form of liver transplant recipients treated with ledipasvir/sofosbuvir without ribavirin. In a retrospective analysis of 162 post-transplant patients from six centres with HCV genotype 1, 2, 3, 4 or 6 recurrence with SVR data after ledispasvir/sofosbuvir with or without ribavirin by Kwok et al., the SVR rate of all patients treated with ledipasvir/sofosbuvir without ribavirin was 96%. 19 This study adds to the literature by describing the largest known cohort of post-liver transplant patients to date from a single-centre treated outside of a clinical trial using ledipasvir/sofosbuvir therapy without ribavirin for chronic HCV infection. In addition, we report on genotype 1 patients exclusively, thereby avoiding other genotypes altering the results. In this real world experience from a high volume transplant centre, combination treatment with ledipasvir/sofosbuvir achieved an SVR12 of 95.9% by ITT analysis.
Interestingly, our study revealed that a positive week 8 viral load was a significant positive predictor of SVR failure. The majority of patients (73.9% of the entire cohort) achieved a rapid virological response (undetectable HCV viral load at week 4); however, this was not a statistically significant predictor of SVR, consistent with previous studies. These results suggest that a positive week 8 viral load may necessitate prolongation of treatment duration; however, our analysis is underpowered to further explore this question. Subsequent studies aimed specifically at the cohort with positive week 8 viral load are necessary.
We acknowledge the limitation of the retrospective nature of this study. Our power is low to detect predictors of SVR failure. Nonetheless, some patients do fail after taking several weeks of expensive therapy, and identifying patients at high risk of failure is thus important, so the analysis of predictors of SVR failure is included in the manuscript for hypothesis generation. Strengths of the study include the ITT design and that this was an effectiveness study not supported by industry funding. The results are thus more externally valid to the 
